Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 1/20 | 0.47 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.41 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.41 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13136741 | 0.87 | ALDH1A1 (0.49) | AKR1C3MAPK1ALDH1A1LMNAMAPT | |
| SCHEMBL5582367 | 0.85 | EGLN1 (0.43) | ACLYEGLN1ALDH1A1LMNAKDM4E | |
| SCHEMBL2355633 | 0.83 | SHMT1 (0.41) | ALDH1A1SHMT1SHMT2KDM4ESCN2A | |
| SCHEMBL509730 | 0.83 | SUCNR1 (0.50) | ALDH1A1SHMT1SHMT2KDM4ESUCNR1 | |
| SCHEMBL14089365 | 0.82 | SUCNR1 (0.43) | ACLYEGLN1AKR1C3MAPK1ALDH1A1 | |
| SCHEMBL7103710 | 0.82 | SUCNR1 (0.43) | ACLYEGLN1AKR1C3MAPK1ALDH1A1 | |
| SCHEMBL811973 | 0.80 | KDM4E (0.47) | ACLYEGLN1AKR1C3MAPK1ALDH1A1 | |
| SCHEMBL10923842 | 0.78 | ALDH1A1 (0.50) | ACLYAKR1C3MAPK1ALDH1A1LMNA | |
| SCHEMBL12650135 | 0.77 | NPC1 (0.45) | ALDH1A1LMNAKDM4E | |
| SCHEMBL19068062 | 0.77 | MAPT (0.58) | MAPK1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987500-B2 | 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987500-B2 | 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140039215-A1 | 4-Biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-20140039215-A1 | 4-Biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-02-06 | — | — | US | disclosed |
| US-8586783-B2 | 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2013-11-19 | — | — | US | disclosed |
| US-20130018202-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2013-01-17 | — | — | US | disclosed |
| US-8168566-B2 | 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-01 | — | — | US | disclosed |
| US-8119566-B2 | use as pesticides and/or herbicides and/or microbicides; for the selective control of weeds; synergistic; low application rates and concentrations; in particular in cereals (especially wheat) | BAYER CROPSCIENCE AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20120040963-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20080188371-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039215-A1 | 4-Biphenyl-substituted pyrazolidin-3,5-dione derivatives | DDT, CYP4X1, HPD | ACLY 759/4885EGLN1 1066/4885AKR1C3 1156/4885 |
| US-20120040963-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | ACLY 759/4885EGLN1 1066/4885AKR1C3 1156/4885 |
| US-20080188371-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | ACLY 759/4885EGLN1 1066/4885AKR1C3 1156/4885 |
| US-20130018202-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | ACLY 759/4885EGLN1 1066/4885AKR1C3 1156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.